Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
Delayed Quote. Delayed Nasdaq - 12/03 04:00:01 pm
15.84 USD   -3.88%
11/22Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
AQ
11/20Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
BU
11/20Exelixis Announces Detailed Results from Phase 3 Cosmic-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer At Esmo Asia Virtual Oncology Week 2021
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis : Reports Final Results From Phase 3 Trial of Thyroid Cancer Treatment

09/20/2021 | 03:45pm EST


© MT Newswires 2021
All news about EXELIXIS, INC.
11/22Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
AQ
11/20Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantin..
BU
11/20Exelixis Announces Detailed Results from Phase 3 Cosmic-312 Pivotal Trial of Cabozantin..
CI
11/09Exelixis Says Enrollment Complete For Phase 3 Trial For Cabozantinib in Combination Wit..
MT
11/09Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
BU
11/09Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozan..
CI
11/03Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November ..
BU
11/03Jefferies Starts Exelixis' at Buy with $28 Price Target
MT
11/03Fresh data highlights strength of US economy ahead of Fed meeting
11/03HC Wainwright Adjusts Price Target on Exelixis to $52 From $65, Keeps Buy Rating
MT
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2021 1 336 M - -
Net income 2021 161 M - -
Net cash 2021 1 032 M - -
P/E ratio 2021 31,8x
Yield 2021 -
Capitalization 5 012 M 5 012 M -
EV / Sales 2021 2,98x
EV / Sales 2022 2,38x
Nbr of Employees 773
Free-Float 98,0%
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 15,84 $
Average target price 29,77 $
Spread / Average Target 87,9%
EPS Revisions
Managers and Directors
Michael M. Morrissey President, Chief Executive Officer & Director
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Dana T. Aftab Executive Vice President-Business Operations
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.-18.29%5 012
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819